Form 4: Maravai LifeSciences Executive Andrew Burch Reports Stock Disposal for Tax Obligations

Sentiment:

SEC Form 4 Filing


Andrew Burch, President of Nucleic Acid Production at Maravai LifeSciences, disposed of 16,758 shares to cover tax obligations related to vesting restricted stock units.

Summary

  • On April 15, 2024, Andrew Burch, President of Nucleic Acid Production at Maravai LifeSciences Holdings, Inc., disposed of 16,758 shares of Class A Common Stock.
  • The transaction was executed to satisfy tax withholding obligations related to the vesting of restricted stock unit awards.
  • The shares were disposed of at a price of $8.11 per share.
  • Following the transaction, Burch beneficially owns 420,035 shares of Maravai LifeSciences Holdings, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock transactions by a company executive for tax purposes. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. This transaction is related to tax obligations, which is a common reason for stock disposals by executives.

Stakeholder Impact

  • The transaction has a minimal impact on shareholders as it is a routine disposal of shares for tax purposes by an executive.

Key Dates

DateDescription
04/15/2024Date of stock disposal transaction
04/16/2024Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.